Technical Analysis for KZIA - Kazia Therapeutics Limited

Grade Last Price % Change Price Change
D 9.52 -4.90% -0.49
KZIA closed down 4.9 percent on Thursday, May 13, 2021, on 85 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical KZIA trend table...

Date Alert Name Type % Chg
Expansion Breakdown Bearish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -4.90%
Narrow Range Bar Range Contraction -4.90%
NR7 Range Contraction -4.90%
Multiple of Ten Bullish Other -4.90%
Older End-of-Day Signals for KZIA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1 ATR about 6 hours ago
Down 5% about 7 hours ago
Down 3% about 7 hours ago
Fell Below Previous Day's Low about 7 hours ago
Lower Bollinger Band Support about 7 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Kazia Therapeutics Limited Description

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer ATM Cancer Treatments Chemotherapy Ovarian Cancer Blastoma Cancer Treatment Cancer Cell Glioma Neuroblastoma Cytoskeleton Novogen Pharmaceutical Research Diffuse Intrinsic Pontine Glioma

Is KZIA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 15.85
52 Week Low 2.55
Average Volume 115,365
200-Day Moving Average 8.78
50-Day Moving Average 11.11
20-Day Moving Average 10.59
10-Day Moving Average 10.19
Average True Range 0.66
ADX 19.16
+DI 13.47
-DI 29.32
Chandelier Exit (Long, 3 ATRs ) 10.61
Chandelier Exit (Short, 3 ATRs ) 11.08
Upper Bollinger Band 11.56
Lower Bollinger Band 9.61
Percent B (%b) -0.05
BandWidth 18.46
MACD Line -0.45
MACD Signal Line -0.34
MACD Histogram -0.112
Fundamentals Value
Market Cap 90.08 Million
Num Shares 9.46 Million
EPS -0.92
Price-to-Earnings (P/E) Ratio -10.35
Price-to-Sales 0.00
Price-to-Book 9.04
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.00
Resistance 3 (R3) 11.03 10.56 10.76
Resistance 2 (R2) 10.56 10.18 10.55 10.67
Resistance 1 (R1) 10.04 9.95 9.81 10.01 10.59
Pivot Point 9.57 9.57 9.45 9.56 9.57
Support 1 (S1) 9.05 9.19 8.82 9.03 8.45
Support 2 (S2) 8.58 8.96 8.57 8.37
Support 3 (S3) 8.06 8.58 8.28
Support 4 (S4) 8.04